DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 46.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 25,347 shares of the medical device company’s stock after selling 22,196 shares during the quarter. Lecap Asset Management Ltd.’s holdings in DexCom were worth $1,971,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Jennison Associates LLC lifted its position in DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after acquiring an additional 6,544,102 shares during the period. Westfield Capital Management Co. LP lifted its position in DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares during the period. Two Sigma Advisers LP lifted its holdings in shares of DexCom by 182.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after buying an additional 739,000 shares during the period. Intech Investment Management LLC lifted its holdings in shares of DexCom by 2,083.0% in the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock valued at $25,967,000 after buying an additional 369,587 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of DexCom by 53.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock valued at $66,352,000 after buying an additional 345,114 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,342 shares of company stock valued at $3,628,069. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Down 0.5 %

Shares of NASDAQ DXCM opened at $88.32 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The stock has a market cap of $34.50 billion, a PE ratio of 52.89, a P/E/G ratio of 2.23 and a beta of 1.14. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a 50-day moving average of $81.35 and a 200 day moving average of $75.69.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DXCM. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Sanford C. Bernstein upped their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Royal Bank of Canada reduced their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their price target for the stock from $85.00 to $115.00 in a report on Monday. Finally, Leerink Partners reduced their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.41.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.